From Kinases to Diseases: Investigating the Role of AMPK in Human Pathologies

Abstract

Adenosine Monophosphate-Activated Protein Kinase (AMPK) is the major conserved regulator of cellular metabolism in eukaryotic cells, from yeast to mammals. Given its pivotal role, it is not surprising that alterations in its function may contribute to the pathogenesis of numerous human diseases. Indeed, AMPK has become a promising therapeutic target for several pathologies. In this context, significant efforts have been dedicated to discovering new pharmacological agents capable of activating AMPK based on next-generation sequencing (NGS) technology and personalized medicine. Thanks to computational methodologies and high-throughput screening, the identification of small molecules and compounds with the potential to directly activate AMPK or modulate its intricate signaling network has become viable. However, the most widely used drug to activate AMPK in human patients is still metformin, which has shown promising results in the treatment of various diseases, such as type II diabetes, atherosclerosis, Alzheimer’s disease, Huntington’s disease, and several types of cancer. In this review, we present a comprehensive analysis of the involvement of AMPK in human pathology, emphasizing its significant potential as a therapeutic target.

Potential application of traditional Chinese medicine in age-related macular degeneration—focusing on mitophagy

“…AMP-activated protein kinase (AMPK) is also related to the regulation of mitophagy. AMPK, a ubiquitously expressed serine/ threonine kinase, is a highly conserved sensor of cellular energy and nutritional status and a major regulator of cellular metabolism (Rey and Tamargo-Gómez, 2023). AMPK activation plays a role in controlling oxidative stress, inflammation, glycolipid metabolism, FUNDC1 and AMPK are involved in the regulation of mitophagy.…”

Lysosomal Dysfunction: Connecting the Dots in the Landscape of Human Diseases

“…Alternatively, autophagy is also regulated by other proteins such as AMPK (AMPactivated protein kinase). In this sense, AMPK inhibits mTORC1 activity through the direct phosphorylation of Raptor and activation of TSC2 (tuberous sclerosis complex 2), which acts as a negative regulator of mTORC1 activity [22]. In addition, AMPK also activates the ULK complex, phosphorylating the ULK1 protein at different residues [23].…”